Developing New Patient Start Likelihood Programs in Pharma
Clarkston partnered with a mid-sized biopharmaceutical client to create new patient start likelihood programs, which predict when patient treatment will progress and when they may be eligible for the client’s product. Read a synopsis of the project below or download the full case study.
Download the New Patient Start Likelihood Programs Case Study Here
New patient start likelihood models support commercial teams by educating the treating physicians about identified patients, allowing them to mobilize resources at the right time to drive sales and deliver life-saving treatments.
In rare diseases, the populations are small to begin with, so finding a patient when they need the client’s treatment is critical. The predictive models focus on the individual patient treatment journey, rather than physician-level data alone, and a combination of open claims data sources are used for better coverage. Considerations for proper use of these datasets include patient deduplication, data completeness, and processing delay, incorporated across multiple sources. The Clarkston team also worked through several iterations of treatment line definitions to get an optimal snapshot of the patient journey.
Continuous performance monitoring allows the team to track predictions and execute retraining as needed. It also provides a benchmark for improvement explorations, like new feature development and dynamic thresholding. Monitoring continues after the delivery phase via alert-level feedback from field teams. Successful adoption of this program is strongly attributed to the clarity and frequency of communication between the data science and field teams.
The first new patient start likelihood program has become a cornerstone of the client’s commercial outreach strategy. Strong reception of the program has led the client to request similar programs for two additional therapeutic areas, both of which were productionized by Clarkston in time for initial drug launch. Quick delivery was instrumental in educating the right physicians on the new drug efficiently, allowing patients to receive improved treatment sooner. The new patient start likelihood program is now an expected element for new products the client brings to market.
Download the New Patient Start Likelihood Programs case study, and learn more about our Life Sciences Commercial Consulting Services by contacting us below.
Contributions by Shannon O’Hara
